All Oncology News

Shubham Pant, MD, MBBS, explores frontline chemotherapy decision-making in metastatic pancreatic cancer.

Sequential intracerebroventricular and intraventricular administration of CAR T-cell therapy was better tolerated in pediatric central nervous system tumors.

Vorasidenib is being integrated in the real-world setting for the treatment of patients with IDH-mutated glioma.

18F-Fluciclovine PET/MRI detected disease progression and ruled out disease in non-progressors among patients with solid tumor brain metastases.

Phase 2 study finds 177Lu-Dotatate safe in advanced intracranial meningioma, with a 6-month PFS rate surpassing historical benchmarks.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, lung cancer, urothelial cancer, and prostate cancer.

Erdafitinib had a safety profile that was deemed tolerable in patients with recurrent or progressive IDH wild-type glioma harboring F3T3 gene fusions.

Eflornithine plus lomustine produced superior OS and PFS outcomes vs lomustine in WHO grade 3 IDH-mutated astrocytoma.

Temozolomide plus radiotherapy significantly improved OS vs radiotherapy alone in IDH-mutant low-grade gliomas without codeletions of 1q and 19q.

Long-term ReNeu results showed deeper, more durable responses to mirdametinib in NF1-PN with extended treatment in both adults and children.

HER2-directed CAR T-cell therapy was safe in patients with brain/leptomeningeal metastases from HER2-positive breast cancer.

The FDA approved 5 therapeutic options spanning lung cancer, urothelial cancer, NF1-associated PNs, and AL amyloidosis.

B7-H3–directed CAR T-cell therapy given intraventricularly was well tolerated and showed early efficacy signals in patients with recurrent glioblastoma.

Mirdametinib had clinical activity and was deemed well tolerated in MEK inhibitor–naive pediatric patients with recurrent/progressive low-grade glioma.

The RP2D of regorafenib when given with temozolomide and radiotherapy in patients with MGMT-methylated, IDH wild-type glioblastoma was 120 mg.

Vorasidenib plus temozolomide was safe in glioma harboring IDH1/2 mutations.

The FDA has approved neoadjuvant/adjuvant enfortumab vedotin plus pembrolizumab for cisplatin-ineligible muscle-invasive bladder cancer.

A rolling NDA submission for zipalertinib in NSCLC with EGFR exon 20 insertion mutations who received prior chemotherapy has been initiated.

Will the FDA approve zidesamtinib for ROS1-positive advanced non–small cell lung cancer after a prior TKI?

Northwestern Medicine researchers discovered only 35% of patients would have qualified for lung cancer screening according to the U.S. Preventive Services Task Force (USPSTF) criteria.

Joshua Richter, MD, discusses the exploration of CELMoDs in the treatment of patients with multiple myeloma.

Maurie Markman, MD, discusses the evolving role of measurements in cancer care.

Carlo Visco, MD, discusses phase 2 FIL_V-RBAC results showing venetoclax plus RBAC achieved a meaningful PFS and manageable toxicity in high-risk MCL.

The FDA OKs the Oncomine Dx Target Test to identify patients with HER2 TKD–mutant NSCLC eligible for sevabertinib, enabling targeted treatment selection.

Denosumab-desu (Osvyrti and Jubereq) received FDA approval in the same indications as reference denosumab (Prolia and Xgeva).

Investigators at Moffitt Cancer Center have developed a novel biomaterial-based system that induces the formation of tertiary lymphoid-like structures.

Mecbotamab vedotin showed promising survival gains and manageable safety in treatment-refractory soft tissue sarcomas.

Shubham Pant, MD, MBBS, and Ryan W. Huey, MD, MS, discuss OXPHOS pathway inhibition in pancreatic cancer with lixumistat.

The FDA approved sevabertinib for previously treated, nonsquamous non–small cell lung cancer with HER2 TKD activating mutations.

The FDA has granted traditional approval to tarlatamab-dlle (Imdelltra) for the treatment of select patients with ES-SCLC.